Versant Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Versant Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5	Closed	-$510	–	2101
2023 Q2	$510	Buy	+5	New	+$473	﹤0.01%	1829

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Versant Capital Management's RETA Position: Q3 2023 in Review

Versant Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 5 shares — an estimated $510 sold.

Versant Capital Management first reported a position in RETA in Q2 2023 and held it in 1 quarter. The position peaked at $510 in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Versant Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Versant Capital Management sold 5 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $510.
Versant Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2023 and held it in 1 quarter.
Versant Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $510 in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Versant Capital Management's 13F filing for Q3 2023, filed 12 Oct 2023.